Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

NCT01514344 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma

Interventions

DRUG: intralesional rituximab
BIOLOGICAL: supplemental autologous serum

Sponsor

Andres J. M. Ferreri